Glycopyrrolate / Indacaterol Dosage
Medically reviewed on April 4, 2017.
Applies to the following strengths: 15.6 mcg-27.5 mcg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance
UTIBRON NEOHALER (R):
-1 inhalation (glycopyrrolate 15.6 mcg-indacaterol 27.5 mcg) orally TWICE a day (in the morning and in the evening)
-For each inhalation, administer the content of 1 capsule using the NEOHALER device.
-More frequent administration or a greater number of inhalations (more than 1 capsule twice a day) is not recommended. Do not use 2 capsules at one time.
ULTIBRO BREEZHALER (R):
-1 inhalation (glycopyrrolate 50 mcg-indacaterol 110 mcg) orally ONCE a day
-Inhale orally the content of one capsule using the BREEZHALER inhaler.
Use: Long term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema
Renal Dose Adjustments
Mild to moderate renal dysfunction: No adjustment recommended.
Severe renal dysfunction: Benefit should outweigh the potential risk.
End-stage renal disease: Benefit should outweigh the potential risk.
Liver Dose Adjustments
Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction: No studies have been performed.
US BOXED WARNING(S):
-Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Data from a large placebo-controlled U.S. study that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of all LABAs, including indacaterol, one of the active ingredients in this drug.
-The safety and efficacy of this drug in patients with asthma have not been established. This drug is not indicated for the treatment of asthma.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Hemodialysis: Benefit should outweigh the potential risk.
Peritoneal dialysis: Data not available
-Administer this drug at the same time of the day.
-The recommended daily dose should not be exceeded.
-This drug is for oral inhalation only.
-To ensure proper use of the inhalation device, see Instructions for its use.
-Capsules should be stored in the blister, and only removed immediately before use with the inhaler device.
Limitations of use:
-This drug is not indicated for the relief of acute bronchospasm or for the treatment of asthma.
-Patients should read the medication guide and instructions for the use of this drug.
-A rescue inhaler should be provided to patients to treat acute symptoms. Patients should be instructed on how to use the rescue inhaler.
-Notify the physician immediately if experiencing any of the following: Worsening of symptoms; decreasing effectiveness of inhaled, short-acting beta2-agonists; need for more inhalations than usual of the inhaled, short-acting beta2-agonists; significant decrease in lung function as outlined by the physician.
-Therapy with this drug should not be stopped without physician/provider guidance since symptoms may recur after discontinuation.
-Discontinue previous regular use of short acting beta2-agonist and use them only for the symptomatic relief of acute symptoms.
-Consult a provider immediately if symptoms of eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema develop.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about glycopyrrolate/indacaterol
- Glycopyrrolate/indacaterol Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- Drug class: bronchodilator combinations
- Glycopyrrolate and indacaterol inhalation
- Indacaterol and Glycopyrrolate
- Indacaterol and glycopyrrolate Inhalation (Advanced Reading)
Other brands: Utibron Neohaler